ADC Linker

ADC 抗体偶联药物是将高特异性的单克隆抗体 (antibody) 与高活性的小分子毒性药物 (payload) 通过连接子 (linker) 连接而成。对于肿瘤治疗具有靶向性高，特异性强，毒副作用小等优点。ADC 药物进入体内后，抗体部分与肿瘤细胞表面的靶向抗原结合 (binding)，肿瘤细胞会将 ADC 分子内吞。之后 ADC 药物会在溶酶体中分解，释放出活性的化药毒物，破坏 DNA 或阻止肿瘤细胞分裂，起到杀死细胞的作用。一个理想的 ADC 抗体偶联药物需要抗原、抗体、毒素分子、连接子四部分的完美结合。

1.ADC Linker

参考文献

1、A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

BLOOD, 13 JUNE 2013. VOLUME 121, NUMBER 24

2、Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia

Vol. 7, 1490–1496, June 2001 Clinical Cancer Research

3、Antibody-Drug Conjugate Targets

Current Cancer Drug Targets, 2009, 9, 982-1004

4、Phase I Study of Trastuzumab-DM1, an HER2 AntibodyDrug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive static Breast Cancer

VOLUME 28 NUMBER 16 JUNE 1 2010 JOURNAL OF CLINICAL ONCOLOGY